You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung CancerPepinemab in Combination with Avelumab in NSCLC
|
|---|---|
| Published in |
Clinical Cancer Research, April 2021
|
| DOI | 10.1158/1078-0432.ccr-20-4792 |
| Pubmed ID | |
| Authors |
Michael R. Shafique, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae E. Pastore, Crystal L. Mallow, Ernest Smith, Vikas Mishra, Andreas Schröder, Kevin M. Chin, Joseph T. Beck, Megan A. Baumgart, Ramaswamy Govindan, Nashat Y. Gabrail, Alexander I. Spira, Nagashree Seetharamu, Yanyan Lou, Aaron S. Mansfield, Rachel E. Sanborn, Jonathan W. Goldman, Maurice Zauderer |
X Demographics
The data shown below were collected from the profiles of 20 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 8 | 40% |
| Italy | 2 | 10% |
| India | 1 | 5% |
| United Kingdom | 1 | 5% |
| Unknown | 8 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 17 | 85% |
| Scientists | 1 | 5% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
| Practitioners (doctors, other healthcare professionals) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 15% |
| Other | 3 | 12% |
| Unspecified | 2 | 8% |
| Student > Postgraduate | 2 | 8% |
| Student > Doctoral Student | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 12 | 46% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 23% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 12% |
| Unspecified | 2 | 8% |
| Business, Management and Accounting | 1 | 4% |
| Chemical Engineering | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 13 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 236. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2023.
All research outputs
#161,330
of 25,554,853 outputs
Outputs from Clinical Cancer Research
#66
of 13,259 outputs
Outputs of similar age
#4,987
of 455,969 outputs
Outputs of similar age from Clinical Cancer Research
#2
of 223 outputs
Altmetric has tracked 25,554,853 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,259 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 455,969 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 223 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.